Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 145040
Corporate User License Price USD 6000
Corporate User License Price INR 435120
Site License Price USD 4000
Site License Price INR 290080
Request a Quote

Report Title

Glomerulonephritis-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Glomerulonephritis-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Glomerulonephritis-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Glomerulonephritis-Pipeline Review, H1 2017



Executive Summary

Glomerulonephritis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glomerulonephritis-Pipeline Review, H1 2017, provides an overview of the Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline landscape.

Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat known as strep throat, immune diseases, such as lupus, Type 1 diabetes and type 2 diabetes and viruses, such as HIV, hepatitis B virus, and hepatitis C virus. Factors that increase chances of getting glomerulonephritis include family history of glomerulonephritis, the presence of a known cause of glomerulonephritis and high blood pressure. Common symptoms of glomerulonephritis are blood in the urine (dark, rust-colored, or brown urine), foamy urine, swelling (edema) of the face, eyes, ankles, feet, legs, or abdomen. Treatment will depend on the cause of glomerulonephritis such as medications, lifestyle changes, dialysis and transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glomerulonephritis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 8, 2, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Glomerulonephritis (Genito Urinary System And Sex Hormones).

The pipeline guide reviews pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Glomerulonephritis-Overview

Glomerulonephritis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Glomerulonephritis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glomerulonephritis-Companies Involved in Therapeutics Development

Achillion Pharmaceuticals Inc

Alexion Pharmaceuticals Inc

Anthera Pharmaceuticals Inc

Biogen Inc

BLR Bio LLC

ChemoCentryx Inc

Dimerix Bioscience Pty Ltd

GlaxoSmithKline Plc

Mallinckrodt Plc

Omeros Corp

Pfizer Inc

Pharmalink AB

Ra Pharmaceuticals Inc

Retrophin Inc

Rigel Pharmaceuticals Inc

Shire Plc

Visterra Inc

Glomerulonephritis-Drug Profiles

(irbesartan + propagermanium)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACH-4471-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMY-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVX-002-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BaxB-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BaxG-03-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

belimumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

blisibimod-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLR-400-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

budesonide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCX-140-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eculizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fostamatinib disodium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

losmapimod-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit ITGAM for Cardiovascular, Immunology and Kidney Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-721-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-1355-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Enzyme for Immunoglobulin A Nephropathy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHP-627-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Factor D for PNH and Dense Deposit Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Factor D for Paroxysmal Nocturnal Hemoglobinuria and Membranoproliferative Glomerulonephritis Type II-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sparsentan-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit Factor D for Age-Related Macular Degeneration, Paroxysmal Nocturnal Hemoglobinuria and Renal Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-5484-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CD40 for Membranous Glomerulonephritis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAR-200-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIS-649-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glomerulonephritis-Dormant Projects

Glomerulonephritis-Discontinued Products

Glomerulonephritis-Product Development Milestones

Featured News & Press Releases

Mar 01, 2017: Retrophin Provides Sparsentan Regulatory Update

Feb 28, 2017: Achillion Pharmaceuticals to Support a Natural History Study of C3 Glomerulopathy, a Rare Renal Disorder, Conducted by Experts at Imperial College London

Jan 09, 2017: ChemoCentryx Provides Update on Lead Program CCX140

Nov 30, 2016: World Renowned Experts Join Variant Pharmaceuticals' Scientific Advisory Board

Nov 21, 2016: Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016

Nov 19, 2016: Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016

Oct 21, 2016: Retrophin to Present Additional Data from Phase 2 DUET Study of Sparsentan in Late-Breaking Oral Session at ASN Kidney Week 2016

Sep 07, 2016: Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis

Aug 01, 2016: Dimerix announces outcomes of DMX-200 pre-IND meeting with the FDA

May 17, 2016: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel for Rare Cause of Nephrotic Syndrome

Mar 30, 2016: Retrophin Completes Enrollment of Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis

Mar 04, 2016: Amyndas' lead candidate AMY-101 receives orphan drug status from the FDA and the EMA for the treatment of C3 glomerulopathy

Dec 14, 2015: Dimerix receives Orphan Designation for its lead drug candidate targeting patients with chronic kidney disease

Nov 16, 2015: Retrophin Receives European Orphan Drug Designation for Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis

Jan 09, 2015: Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Glomerulonephritis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Glomerulonephritis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Glomerulonephritis-Pipeline by Achillion Pharmaceuticals Inc, H1 2017

Glomerulonephritis-Pipeline by Alexion Pharmaceuticals Inc, H1 2017

Glomerulonephritis-Pipeline by Anthera Pharmaceuticals Inc, H1 2017

Glomerulonephritis-Pipeline by Biogen Inc, H1 2017

Glomerulonephritis-Pipeline by BLR Bio LLC, H1 2017

Glomerulonephritis-Pipeline by ChemoCentryx Inc, H1 2017

Glomerulonephritis-Pipeline by Dimerix Bioscience Pty Ltd, H1 2017

Glomerulonephritis-Pipeline by GlaxoSmithKline Plc, H1 2017

Glomerulonephritis-Pipeline by Mallinckrodt Plc, H1 2017

Glomerulonephritis-Pipeline by Omeros Corp, H1 2017

Glomerulonephritis-Pipeline by Pfizer Inc, H1 2017

Glomerulonephritis-Pipeline by Pharmalink AB, H1 2017

Glomerulonephritis-Pipeline by Ra Pharmaceuticals Inc, H1 2017

Glomerulonephritis-Pipeline by Retrophin Inc, H1 2017

Glomerulonephritis-Pipeline by Rigel Pharmaceuticals Inc, H1 2017

Glomerulonephritis-Pipeline by Shire Plc, H1 2017

Glomerulonephritis-Pipeline by Visterra Inc, H1 2017

Glomerulonephritis-Dormant Projects, H1 2017

Glomerulonephritis-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Achillion Pharmaceuticals Inc, Alexion Pharmaceuticals Inc, Anthera Pharmaceuticals Inc, Biogen Inc, BLR Bio LLC, ChemoCentryx Inc, Dimerix Bioscience Pty Ltd, GlaxoSmithKline Plc, Mallinckrodt Plc, Omeros Corp, Pfizer Inc, Pharmalink AB, Ra Pharmaceuticals Inc, Retrophin Inc, Rigel Pharmaceuticals Inc, Shire Plc, Visterra Inc


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand